Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
Congratulations to Sara Godina on an amazing score!
Congratulations to Sara Godina on an amazing score on her R36 “The impact of neighborhood greenspace on cognitively healthy life years and structural markers of brain health” Well done, Sara!!
